Drug updated on 4/24/2024
| Dosage Form | Powder (oral Inhalation; 62.5 mcg umeclidinium and 25 mcg vilanterol) |
| Drug Class | Anticholinergics and long-acting beta2-adrenergic agonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Summary
- Umeclidinium bromide and vilanterol trifenatate (Anoro Ellipta) is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD), showing superior efficacy in lung function improvement compared to several other dual and mono-bronchodilator therapies.
- Eleven systematic reviews/meta-analyses provide a comprehensive dataset about Anoro Ellipta's effectiveness and safety profile.
- Among traditional agents for COPD, Aclidinium bromide/Formoterol ranks highest in terms of FEV1 improvement, followed by Umeclidinium/vilanterol. This indicates that Anoro Ellipta has significant potential in improving lung function while maintaining a good safety profile comparable to monoclonal antibodies.
- The performance of LABA/LAMA fixed-dose combinations like Anoro Ellipta may vary depending on specific factors such as history and baseline FEV1. However, it generally shows strong efficacy against moderate or severe COPD exacerbations.
- Network meta-analyses suggest no strong evidence of superior benefits among different LAMA/LABA combinations, including Anoro Ellipta, when reducing total exacerbations, all cause mortality after 48 weeks, indicating its comparable performance within this class.
- Each LABA/LAMA combination, including Anoro Ellipta, has distinct profiles, highlighting the need for personalized consideration towards each drug regimen based on a study examining their efficacy/safety profiles.
- Compared to placebo, once-daily LABA/LAMA combinations like Anoro Ellipta show clinically significant improvements in lung function and quality of life, supporting its utility up to one year for mild-moderate COPD patients.
- The effectiveness can significantly vary based on patient history and baseline FEV1, emphasizing the importance of personalizing treatments considering individual characteristics across a wide range of severity from mild-severe airflow limitations.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Anoro Ellipta (umeclidinium bromide and vilanterol trifenatate) Prescribing Information. | 2023 | GlaxoSmithKline, Research Triangle Park, NC |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| 2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients with Stable COPD. | 2023 | Canadian Journal of Respiratory, Critical Care, and Sleep Medicine |
| 2022 GINA Report, global strategy for asthma management and prevention. | 2022 | Global Initiative for Asthma |
| LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations. | 2022 | Journal of Clinical Medicine |
| Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. | 2021 | Archivos de Bronconeumologia |
| 2020 Gold pocket guide to COPD diagnosis, management, and prevention. | 2020 | Global Initiative for Chronic Obstructive Lung Disease |
| COPD-X Concise Guide. | 2020 | Lung Foundation Australia |
| Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence. | 2019 | Canadian Journal of Respiratory, Critical Care, and Sleep Medicine |